Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals's RPA-501?
RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD)....
Data Insights
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals's RPA-501?
RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD)....